Observational studyJournal of patient-reported outcomes2026
Validity, reliability, and longitudinal measurement properties of the Asthma Daytime and Nighttime Symptom Diaries in patients with moderate-to-severe asthma.
Observational study in Journal of patient-reported outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04719832 (A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Who cites it
1 citing paper in PubMed.
- Asthma daytime and nighttime symptom diaries: content validity and qualitative exploration of meaningful change in patients with moderate-to-severe asthma.Journal of patient-reported outcomes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe Asthma Daytime and Nighttime Symptom Diaries (ADSD and ANSD) were developed to provide an accurate and standardized instrument for assessing patient-reported severity of asthma symptoms. While previous evidence supports the content validity and cross-sectional measurement properties of the ADSD and ANSD, the US Food and Drug Administration (FDA) qualification statement for these tools recommended further evaluation of their longitudinal measurement properties and the interpretation of within-patient meaningful change (WPMC). Therefore, two complementary studies were designed to assess cross-sectional and longitudinal measurement properties and estimate thresholds for WPMC for the ADSD/ANSD in patients with moderate-to-severe asthma, responding to measurement gaps identified in the FDA statement. METHODOLOGY: Quantitative evaluation of ADSD/ANSD (score range 0 to 10) measurement properties was performed in a real-world observational study (RWS; ≥16 years old; moderate-to-severe asthma) and a randomized controlled trial (RCT; ≥12 years old; severe asthma with type 2 inflammation). Cross-sectional and longitudinal measurement properties were assessed and WPMC thresholds estimated.
resultsA total of 576 patients with moderate-to-severe asthma were recruited across both studies. The RWS (n = 241) and RCT (n = 335) both found the ADSD/ANSD to have high internal consistency and test-retest reliability with Cronbach's α-coefficients ≥0.94 and intraclass correlation coefficients ≥0.90. Evidence in support of the unidimensional scoring solution for both the ADSD and ANSD was established via confirmatory factor analysis across timepoints and studies, and evidence of construct validity was demonstrated via convergent and known-groups validity testing. In the blinded RCT analysis, the threshold for WPMC was estimated at 1.2 for the ADSD and 1.5 for the ANSD. In the RWS, the WPMC threshold for within-patient improvement was estimated to be from 0.6 to 1.3 for ADSD and from 0.8 to 1.4 for ANSD across 6- and 10-week intervals.
conclusionsThis study directly addresses the evidence gaps identified by the FDA, demonstrating that the ADSD and ANSD are reliable and valid tools for the measurement of daily symptoms in patients with moderate-to-severe asthma, and are capable of detecting WPMC. Values derived from the RCT analysis support a recommendation for thresholds for meaningful within-patient change of 1.2 and 1.5 for the ADSD and ANSD, respectively. CLINICAL
trial registrationGSK ID: 217640; NCT04719832.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.